You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Treatment completion and reasons for non-completion by treatment regimen, Norway 2016

From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study

Treatment completion 3RHI daily 3RPHII weekly OtherIII Total
Number of individuals 399 306 21 726
Duration of treatment (days), median [IQR]* 90 [73–156] 77 [70–98]
Treatment completion
 Completed according to physiciana 357 (89.5) 284 (92.8) 17 (80.9) 658 (90.6)
 Missing information 3 (0.8) 4 (1.3) 7 (1.0)
 Incomplete treatment 39 (10) 18 (5.9) 4 (19.0) 61 (8.4)
Reasons for incomplete treatment
 LTBI excluded 4 (1.0) 4 (0.6)
 Diagnosed with TB disease 1 (0.3)   1 (0.1)
 Patient choice 4 (1.0) 2 (0.7) 6 (0.8)
 Lost to follow-up 1 (0.3) 3 (1.0) 4 (0.6)
 Other or unknown 3 (0.8) 2 (0.7)   5 (0.7)
 Termination due to adverse effectsb 26 (6.5) 11 (3.4) 4 (19.0) 41 (5.6)
  Hepatotoxicity (grade 1–2)c 8 (2.0) 8 (1.1)
  Hepatotoxicity (grade 3–4)c 5 (1.6) 2 (0.7) 1 (4.8) 8 (1.1)
  Gastrointestinal symptoms 10 (2.5) 8 (2.6) 2 (9.5) 20 (2.8)
  Fatigue 6 (1.5) 8 (2.6) 1 (4.8) 15 (2.1)
  Flu-like symptoms 2 (0.5) 4 (1.3) 1 (4.8) 7 (1.0)
  Skin rash 2 (0.5) 1 (0.3) 1 (4.8) 4 (0.6)
  Peripheral neuropathy 1 (0.3)    1 (0.1)
  Joint pain 2 (0.6) 2 (0.3)
  Other symptomsd 2 (0.5) 3 (1.0) 2 (9.5) 7 (1.0)
  1. Data are presented as n (%) or median [interquartile range]
  2. I3RH: rifampicin (R) and isoniazid (H) daily for three months
  3. II3RPH: rifapentine (RP) and isoniazid (H) in 12 weekly doses
  4. IIIOther: rifampicin (R) monotherapy daily for four months (n = 5), Isoniazid (H) monotherapy for six months (n = 13) or combination therapy for TB disease (n = 2) and missing information about drug regimen (n = 1)
  5. *Duration of treatment for those where the clinician reported the treatment as completed
  6. aThe responsible clinician reported that the planned treatment was completed
  7. bMany reported more than one adverse effect
  8. cSeverity of hepatotoxicity was classified according to Common Terminology Criteria for Adverse Events (CTCAE), ULN = upper limits of normal value for serum levels of liver function, grade 1 (>ULN -3.0 × ULN), grade 2 (> 3.0–5.0 × ULN), grade 3 (> 5.0–20.0 × ULN), and grade 4 (> 20.0 × ULN)
  9. dIncludes headache, sleep disorder, and unstable international normalized ratio (INR) for prothrombin time